Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 346-350

  Stock, Jane ^a  

^a European Atherosclerosis Society   (Sweden)

Author keywords

Aches; Associated; CK elevation; Consensus Panel; Diabetes; Diet; EAS; European Atherosclerosis Society; Genetic; Genetic factors; Infection; Lifestyle; Muscle; Muscle pain; SAMS; Statin; Statin therapy; Symptoms; Weakness

Indexed keywords

ANTIFUNGAL AGENT; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; PROTEINASE INHIBITOR;

BACK MUSCLE; BUTTOCK; CALCIUM HOMEOSTASIS; DRUG BLOOD LEVEL; GENETIC SCREENING; HUMAN; MUSCLE MITOCHONDRION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; STATIN ASSOCIATED MUSCLE SYMPTOM; THIGH; CHEMICALLY INDUCED; CONSENSUS; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; MUSCULAR DISEASES; PATHOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; SKELETAL MUSCLE;

CONSENSUS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84939511246     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.049     Document Type: Note

References (32)

1. Efficacy and Safety of LDL-lowering Therapy Among Men and Women: Meta-analysis of Individual Data from 174 000 Participants in 27 Randomised Trials January 9, 2015, Cholesterol Treatment Trialists' (CTT) Collaboration, Lancet Published Online.
2. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc. Drugs Ther. 2005, 19:403-414.
3. Buettner C., Rippberger M.J., Smith J.K., et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am. J. Med. 2012, 125:176-182.
4. Cohen J.D., Brinton E.A., Ito M.K., Jacobson T.A. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 2012, 6:208-215.
5. Zhang H., Plutzky J., Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann. Int. Med. 2013, 158:526-534.
6. El-Salem K., Ababeneh B., Rudnicki S., et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011, 44:877-881.
7. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
8. Ganga H.V., Slim H.B., Thompson P.D. A systematic review of statin-induced muscle problems in clinical trials. Am. Heart J. 2014, 168:6-15.
9. Finegold J.A., Manisty C.H., Goldacre B., BarronAJ Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur. J. Prev. Cardiol. 2014, 21:464-476.
10. Parker B.A., Capizzi J.A., Grimaldi A.S., et al. Effect of statins on skeletal muscle function. Circulation 2013, 127:96-103.
11. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin. Pharmacol. 2009, 9:6. MRC/BHF Heart Protection Study Collaborative Group.
12. Downs J.R., Clearfield M., Tyroler H.A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin. Am. J. Cardiol. 2001, 87:1074-1079.
13. Mancini G.B., Tashakkor A.Y., Baker S., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can. J. Cardiol. 2013, 29:1553-1568.
14. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
15. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc. Drugs Ther. 2003, 17:265-285.
16. Ahmad Z. Statin intolerance. Am. J. Cardiol. 2014, 113:1765-1771.
17. Alfirevic A., Neely D., Armitage J., et al. Phenotype standardization for statin-induced myotoxicity. Clin. Pharmacol. Ther. 2014, 96:470-476.
18. Keating A.J., Campbell K.B., Guyton J.R. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann. Pharmacother. 2013, 47:398-404.
19. Norata G.D., Ballantyne C.M., Catapano A.L. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur. Heart J. 2013, 34:1783-1789.
20. Cannon CP, Improve-it Investigators. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. A Multicenter, Double-blind, randomized study to establish the clinical benefit and safety of Vytorin (ezetimibe/simvastatin tablet) vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469669.pdf.
21. Li Y., Jiang L., Jia Z., et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014, 9:e98611.
22. Taylor B.A., Lorson L., White C.M., Thompson P.D. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015, 238:329-335.
23. Banach M., Serban C., Sahebkar A., et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin. Proc. 2015, 90:24-34. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.
24. Michalska-Kasiczak M., Sahebkar A., Mikhailidis D.P., et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int. J. Cardiol. 2014, 178C:111-116. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.
25. Needham M., Mastaglia F.L. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul. Disord. 2014, 24:4-15.
26. Mikus C.R., Boyle L.J., Borengasser S.J., et al. Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol. 2013, 62:709-714.
27. Limaye V., Bundell C., Hollingsworth P., et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015 Aug, 52(2):196-203. Epub 2015 Jan 6. 10.1002/mus.24541.
28. Zhang P., Verity M.A., Reue K. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab. 2014, 20:267-279.
29. Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., Gut I., Lathrop M., Collins R. SLCO1B1 variants and statin-induced myopathy-a genome wide study. N. Engl. J. Med. 2008, 359:789-799. SEARCH Collaborative Group.
30. Ruaño G., Windemuth A., Wu A.H., et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011, 218:451-456.
31. Mangravite L.M., Engelhardt B.E., Medina M.W., et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013, 502:377-380.
32. Carr D.F., Alfirevic A., Johnson R., et al. GATM gene variants and statin myopathy risk. Nature 2014, 513:E1.